MuseChem services

MuseChem engages in research and development of organic compounds for the chemical, pharmaceutical and agrochemical industries. We provide world class service in synthesis of varieties of products on the milligram to kilogram scale at competitive price. Armed with outstanding chemistry problem solving skills, our teams of well-trained synthetic chemists are capable of handling even the most complex chemical synthesis and characterization projects, and completing projects on your required timeframe.

MuseChem is a leading supplier of custom peptide synthesis services. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, we offer a wide range of peptide synthesis services from bulk API peptides production to complex peptide modifications. We have an experienced team of scientists who are able to choose and optimize the appropriate peptide synthesis method for each peptide, so our peptide synthesis service has a very high success rate. Each peptide comes with a complete quality control package, which includes HPLC and MS Analysis.

MuseChem has experienced team of analytical chemists. With this team, we have strong capability in providing a comprehensive range of analytical solutions to our clients in the pharmaceutical, biotech, medical devices and cosmetics industries. By utilizing state-of-the-art technologies and instrumentation, we offer superior assistance to customers in structure characterization, impurity analysis, product separation and many other analytical services.

Bioconjugation is a strategy to form a stable covalent bond between two molecules, at least one of which is a biomolecule. As a cross-linking technique, bioconjugation has been widely used to create functional biomolecules for specific biomarkers imaging, cellular events tracking, protein biodistribution determination, enzyme function revealing and drug delivery.

Antibody-drug conjugates (ADCs) are a new class of highly potent oncology therapeutics for the treatment of people with cancer. An ADC could be divided into three main structural units: the antibody; the cytotoxic agent (drug); and the linker. The antibody has high affinity for a tumor-associated antigen that has restricted or no expression on normal cells. By combining this unique targeting capability of antibodies with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.